Biotechnology startup Terray has secured a $120 million investment. The company’s Series B funding round, amounting to $120 million, was led by Bedford Ridge Capital. Based in the United States, Terray’s investment round also included participation from NVentures, Maverick Capital, Goldcrest Capital, Madrona Ventures, Two Sigma Ventures, XTX Ventures, Digitalis Ventures, and Alexandria Ventures.

The company announced that it plans to use the new investment to advance its clinical trials and enhance its artificial intelligence platform, tNova.

Founded in 2018 by Jacob Berlin and Eli Berlin, Terray is described as a biotechnology firm focused on the discovery and development of small molecule drugs. The company is discovering molecules and drugs by integrating ultra-high-throughput experiments, generative artificial intelligence, biology, medicinal chemistry, automation, and nanotechnology. To achieve this, Terray has developed an AI platform called tNova. The company’s goal is to find solutions to the most challenging problems related to small molecule therapies.

Small molecule therapy refers to medications used to treat diseases, typically consisting of low-weight chemical compounds. These therapies are designed to alter the function of cells or reduce the effects of specific diseases. Small molecules are usually easily absorbed in the body and reach target cells to exert their effects. Such therapies are commonly used to treat cancer, infections, and many other health issues.


Source